S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
The #1 Energy Stock to Buy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
The #1 Energy Stock to Buy (Ad)
How to Find Penny Stocks to Invest and Trade
ONSemi Is Marching Higher On Great Results
The #1 Energy Stock to Buy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
Can Cummins Power To A New High? 
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
The #1 Energy Stock to Buy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
The #1 Energy Stock to Buy (Ad)
How to Find Penny Stocks to Invest and Trade
ONSemi Is Marching Higher On Great Results
The #1 Energy Stock to Buy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
Can Cummins Power To A New High? 
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
The #1 Energy Stock to Buy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
The #1 Energy Stock to Buy (Ad)
How to Find Penny Stocks to Invest and Trade
ONSemi Is Marching Higher On Great Results
The #1 Energy Stock to Buy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
Can Cummins Power To A New High? 
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
The #1 Energy Stock to Buy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
What do Mastercard Earnings Indicate About Consumer Spending?
The #1 Energy Stock to Buy (Ad)
How to Find Penny Stocks to Invest and Trade
ONSemi Is Marching Higher On Great Results
The #1 Energy Stock to Buy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
Can Cummins Power To A New High? 
NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

$153.13
-2.51 (-1.61%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$151.14
$157.00
50-Day Range
$149.93
$160.47
52-Week Range
$125.36
$169.98
Volume
696,563 shs
Average Volume
460,522 shs
Market Capitalization
$9.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$202.55

Jazz Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
32.3% Upside
$202.55 Price Target
Short Interest
Healthy
4.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.58mentions of Jazz Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$2.97 M Sold Last Quarter
Proj. Earnings Growth
6.13%
From $15.18 to $16.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

85th out of 1,027 stocks

Pharmaceutical Preparations Industry

32nd out of 500 stocks

JAZZ stock logo

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Stock News Headlines

The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
H.C. Wainwright Reaffirms Their Buy Rating on Novan (NOVN)
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Company Calendar

Last Earnings
11/09/2022
Today
2/07/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
3,200
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$202.55
High Stock Price Forecast
$225.00
Low Stock Price Forecast
$187.00
Forecasted Upside/Downside
+32.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-329,670,000.00
Pretax Margin
-2.17%

Debt

Sales & Book Value

Annual Sales
$3.09 billion
Cash Flow
$22.59 per share
Book Value
$64.51 per share

Miscellaneous

Free Float
60,195,000
Market Cap
$9.64 billion
Optionable
Optionable
Beta
0.71

Social Links


Key Executives

  • Bruce C. CozaddBruce C. Cozadd
    Chairman & Chief Executive Officer
  • Daniel N. Swisher
    President
  • Christopher John ToveyChristopher John Tovey
    Chief Operating Officer & Executive Vice President
  • Renée D. Galá
    Chief Financial Officer & Executive Vice President
  • Robert Iannone
    Chief Medical Officer, EVP-Research & Development













JAZZ Stock - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price forecast for 2023?

10 brokers have issued 1 year target prices for Jazz Pharmaceuticals' shares. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they predict the company's stock price to reach $202.55 in the next year. This suggests a possible upside of 32.3% from the stock's current price.
View analysts price targets for JAZZ
or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2023?

Jazz Pharmaceuticals' stock was trading at $159.31 at the start of the year. Since then, JAZZ stock has decreased by 3.9% and is now trading at $153.13.
View the best growth stocks for 2023 here
.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our JAZZ earnings forecast
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its quarterly earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported $4.53 earnings per share for the quarter, beating the consensus estimate of $4.35 by $0.18. The specialty pharmaceutical company had revenue of $940.65 million for the quarter, compared to analysts' expectations of $939.88 million. Jazz Pharmaceuticals had a negative net margin of 0.52% and a positive trailing twelve-month return on equity of 30.71%.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of $17.20-$17.85 for the period, compared to the consensus estimate of $17.41. The company issued revenue guidance of $3.60 billion-$3.70 billion, compared to the consensus revenue estimate of $3.65 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.54%), Wedge Capital Management L L P NC (0.40%), Retirement Systems of Alabama (0.28%), Sumitomo Mitsui Trust Holdings Inc. (0.28%), Todd Asset Management LLC (0.28%) and Allspring Global Investments Holdings LLC (0.20%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone, Samantha Pearce and Seamus Mulligan.
View institutional ownership trends
.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $153.13.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.64 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329,670,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

The company employs 3,200 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 2/7/2023 by MarketBeat.com Staff